Biogen CEO: Crush drug prices, and you crush drug R&D
This stance on keeping drug pricing aloft helps Biogen CEO George Scangos rationalize the ever-increasing price of its multiple sclerosis drug Avonex.
Morning Read: Obama to sit down with biopharma CEOs to talk Trans-Pacific Partnership agreement
Also, CytomX Therapeutics brings in $80 million, Vertera Spine won FDA 510(k) clearance and John Boehner is stalling on a deal that could potentially create massive increases in Medicare premiums.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Biogen CEO rehashes old ALS clinical trial: “It was the single-most negative trial I’ve ever seen.”
Biogen‘s made headlines of late for committing $2.5 billion on a Alzheimer’s drug development gamble – and, notably, preparing for a return to the ALS market. Making such broad commitments can stir a lot of hope up among a desperate patient base – something CEO George Scangos has learned a lesson or two about by now. Two years ago, Biogen famously halted Phase 3 […]
Top healthcare executives name the CEO they’d trade places with if given the chance
At the J.P. Morgan Healthcare Conference this week some of the biggest names in healthcare gathered to discuss the state of the biopharmaceuticals sector. Amidst all of the commotion, some executives took a moment to tell CNBC‘s Meg Tirrell which CEO (in any industry) they’d most like to trade places with if given the chance. […]